Public Funding and Public Benefit: Balancing Commercialization and Equity in Health Innovation

Abstract

Public funding plays a critical role in advancing health innovation, particularly in high-risk areas such as vaccine development and pandemic preparedness. However, the relationship between public investment and public benefit remains contested, especially when commercialization processes prioritize private returns over equitable access. This paper examines the tension between public funding, commercial incentives, and public health outcomes, arguing that public benefit is not an automatic outcome of public investment but must be actively negotiated. Drawing on existing literature and recent global health experiences, including the COVID-19 pandemic, the study identifies key limitations in current funding models, particularly their emphasis on risk minimization and insufficient mechanisms for ensuring equitable access. The paper proposes a “Balanced Public Return Framework” that integrates risk-sharing, access conditions, commercial incentives, and accountability mechanisms to better align financial structures with public health goals. The findings highlight the importance of structured negotiation strategies and adaptive financing models to ensure that public investments generate meaningful and equitable health outcomes while sustaining innovation.